Is a sustained release formulation of bupivacaine using our TRANSDUR® technology to provide pain relief for patients suffering from localized pain such as Post-Herpetic Neuralgia (post-shingles pain or PHN).
View complete product pipeline
November 13, 2013DURECT Announces Closing of Public Offering of Common Stock
November 08, 2013DURECT Announces Pricing of Public Offering of Common Stock
November 07, 2013DURECT Announces Proposed Public Offering of Common Stock
November 04, 2013DURECT Corporation Announces Third Quarter 2013 Financial Results and Update of Programs